Poster
Next-generation humanized NKG mouse platforms enable pharmacodynamic and antitumor evaluation of in vivo CAR therapies
Evaluating two complementary humanized NKG mouse platforms for preclinical testing of in vivo CAR therapies. huHSC-NKG-ProF mice supported longitudinal pharmacodynamic assessment of CD19-targeting CAR-mediated B-cell depletion, while T-cell-rich huPBMC-NKG mice enabled rapid antitumor evaluation of LNP-delivered BCMA-targeting CAR in a multiple myeloma xenograft model.

Overview
In vivo CAR therapies generate CAR-expressing immune cells directly in the patient, but their translation requires humanized preclinical models that capture CAR generation, pharmacodynamics, and efficacy. We assessed two humanized NKG platforms. huHSC-NKG-ProF mice achieved >25% human CD45+ engraftment from 12 weeks with stable multilineage reconstitution (T, B, NK, myeloid) across three donors; a single CD19-targeting lentiviral in vivo CAR dose produced rapid, sustained peripheral B-cell depletion through Day 56. huPBMC-NKG mice reconstituted ~50% human CD45+ cells, ~95% CD3+ T cells; LNP-delivered BCMA-targeting CAR gave 62% tumor growth inhibition in NCI-H929 xenografts, with CAR+ cells in ~42% of human CD8+ T cells.
Key Insights
Two complementary humanized NKG mouse models — multilineage huHSC-NKG-ProF and T-cell-rich huPBMC-NKG — provide fit-for-purpose platforms for evaluating the pharmacodynamics and antitumor efficacy of in vivo CAR therapies.
- Durable multilineage humanization for longitudinal studies. huHSC-NKG-ProF mice sustained >25% human CD45+ engraftment from week 12 onward with low inter-donor variability across three HSC cohorts, reconstituting CD3+ T, CD19+ B, CD56+ NK, and CD33+ myeloid lineages.
- Clear pharmacodynamic readout for B-cell-directed CAR. A single intravenous dose of CD19-targeting in vivo CAR lentivirus drove rapid and sustained peripheral B-cell depletion through the full 56-day window, while total human leukocyte levels remained stable
- Rapid efficacy model with measurable CAR generation. In T-cell-rich huPBMC-NKG mice bearing BCMA+ NCI-H929 xenografts, LNP-delivered in vivo CAR achieved 62% tumor growth inhibition with CAR expression in ~42% of human CD8+ T cells and no notable body-weight loss.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
